CCM
CLVS

Chiron Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Chiron Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-6,795
Closed -$40K – 488
2020
Q3 		$40K Buy
+6,795
New +$40.7K 0.03% 174

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Chiron Capital Management's CLVS Position: Q4 2020 in Review

Chiron Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q4 2020, closing a stake of 6,795 shares — an estimated $40K sold.

Chiron Capital Management first reported a position in CLVS in Q3 2020 and held it in 1 quarter. The position peaked at $40K in Q3 2020. 159 funds tracked by Wall St. Rank hold CLVS as of Q4 2020.

  • Chiron Capital Management reported no remaining Clovis Oncology, Inc. position as of Q4 2020 after selling out during the quarter.
  • Chiron Capital Management sold 6,795 Clovis Oncology, Inc. shares in Q4 2020, an estimated $40K.
  • Chiron Capital Management first reported a position in Clovis Oncology, Inc. in Q3 2020 and held it in 1 quarter.
  • Chiron Capital Management's Clovis Oncology, Inc. position peaked at $40K in Q3 2020.
  • 159 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2020.

Based on Chiron Capital Management's 13F filing for Q4 2020, filed 5 Mar 2021.